Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

Background/Aims This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods T...

Full description

Bibliographic Details
Main Authors:	Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2019-07-01
Series:	The Korean Journal of Internal Medicine
Subjects:	infusion-related reaction rituximab lymphoma, large b-cell, diffuse prognosis characteristics
Online Access:	http://www.kjim.org/upload/pdf/kjim-2017-036.pdf

Similar Items

Infusion reactions to rituximab administration: algorithm of management
by: D.D. Ivanov, et al.
Published: (2022-06-01)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
by: Ernesto Pérez‐Persona, et al.
Published: (2023-11-01)

Pre-infusion checklist for rituximab in pemphigus vulgaris patients: clinical audit
by: Farah Sagheer, et al.
Published: (2023-07-01)

A modified regimen of rituximab in pemphigus: A retrospective study
by: Tanvi Pradeep Vaidya, et al.
Published: (2020-01-01)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
by: Ashleigh Hennessey, et al.
Published: (2019-08-01)

Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count
by: Maude Plante, et al.
Published: (2021-10-01)

Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications
by: Claudia Bartolini, et al.
Published: (2023-05-01)

Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study
by: Hironobu Nishiura, et al.
Published: (2024-02-01)

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
by: Min Ji Jeon, et al.
Published: (2023-11-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013-09-01)

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
by: Christian Ciolfi, et al.
Published: (2024-01-01)

Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year
by: Surabhi S. Vinod, et al.
Published: (2018-03-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

Acute cryoglobulinemic vasculitis following rituximab infusion for waldenström macroglobulinemia
by: Zach Thornton, BA, et al.
Published: (2023-05-01)

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
by: Fatemeh Saffari, et al.
Published: (2022-01-01)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
by: Young Hoon Kim, et al.
Published: (2020-03-01)

Rituximab resistance in ITP and beyond
by: Zhengrui Xiao, et al.
Published: (2023-07-01)

The BIS and hemodynamic changes in major burn patients according to a slow infusion of propofol for induction
by: Ji Young Bae, et al.
Published: (2011-03-01)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
by: Ahreum Song, et al.
Published: (2022-08-01)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
by: Soo-Jee Jeon, et al.
Published: (2022-07-01)

Rituximab: historia, farmacología y perspectivas Rituximab: history, pharmacology and perspectives
by: Edgardo E. Espinosa Estrada, et al.
Published: (2010-12-01)

Effect of Peel Ply on Resin Flow during Vacuum Infusion
by: Sehun An, et al.
Published: (2023-06-01)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
by: Jeongjae Lee, et al.
Published: (2023-01-01)

Fludarabine and Rituximab in Relapsed or Refractory Hairy Cell Leukmia Variant: A Case Report and Review of Literature
by: Ji Won Lee, et al.
Published: (2018-12-01)

Correction of target-controlled infusion following wrong selection of emulsion concentrations of propofol
by: Yun-Jeong Chae, et al.
Published: (2014-05-01)

Rebound of relapses after discontinuation of rituximab in a patient with MOG-IgG1 positive highly relapsing optic neuritis: a case report
by: Seok-Jin Choi, et al.
Published: (2018-12-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Consciousness Recovery by Rituximab after Seizure Control in Cryptogenic New-Onset Refractory Status Epilepticus
by: Tae-Won Yang, et al.
Published: (2018-12-01)

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation
by: Martalena Ramli, et al.
Published: (2019-06-01)

The Optimizing Background Infusion Mode Decreases Intravenous Patient-Controlled Analgesic Volume and Opioid Consumption Compared to Fixed-Rate Background Infusion in Patients Undergoing Laparoscopic Cholecystectomy: A Prospective, Randomized, Controlled, Double-Blind Study
by: Ki Tae Jung, et al.
Published: (2021-01-01)

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
by: Diankun Liu, et al.
Published: (2021-07-01)

Impact of priming the infusion system on the performance of target-controlled infusion of remifentanil
by: Jong-Yeop Kim, et al.
Published: (2013-05-01)

Rituximab in Autoimmune CNS Disease
by: J Gordon Millichap, et al.
Published: (2014-08-01)

Use of rituximab in systemic lupus erythematosus in children: a review
by: A. N. Arefyeva
Published: (2019-11-01)

Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia
by: Khalid Al-Habsi, et al.
Published: (2015-03-01)

Lupus Nephritis, the therapy and the role of Rituximab in resistant cases
by: Hussein A. Nasir, et al.
Published: (2014-01-01)

Rituximabe na síndrome de Felty refratária Rituximab in the refractory Felty's syndrome
by: Thiago Sotero Fragoso, et al.
Published: (2009-04-01)